The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint.

Authors:
Wollenhaupt J; Albrecht K; Krüger K; Müller-Ladner U.

Journal:
Z Rheumatol

Publication Year: 2013

DOI:
10.1007/s00393-012-1093-6

PMCID:
PMC3567332

PMID:
23392597

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Z Rheumatol

Abbreviation: Z Rheumatol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospecti…
Elaziz MMA; Gamal SM; Fayed A and 3 more (2023) - Transparency Score: 3/6
Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany…
Fiehn C; Zinke S; Haas JS and 4 more (2023) - Transparency Score: 3/6
Survey on the working, training, and research conditions of resident physicians in internistic and …
Proft F; Vossen D; Baraliakos X and 14 more (2023) - Transparency Score: 3/6
COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement.
Kim Y; Kang J; Lee SG and 1 more (2022) - Transparency Score: 2/6
Digitalization and disruptive change in rheumatology.
Richter P; Richter JG; Lieb E and 4 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest On behalf of all authors, the corresponding author states the following: speakers honoraria from Abbott (K.A.); honoraria for consultation, speaking honoraria, and/or reimbursement of travel costs from Abbott, BMS, MSD, Mundipharma, Pfizer, UCB, Roche (K.K.); honoraria from Abbot, BMS, Chugai, MSD, Pfizer, Roche, UCB (U.M.-L.); honoraria from Abbott, BMS, Chugai, MSD, Pfizer, Roche, UCB (J.W.)."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025